<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01819727</url>
  </required_header>
  <id_info>
    <org_study_id>165-301</org_study_id>
    <secondary_id>Prism301</secondary_id>
    <nct_id>NCT01819727</nct_id>
  </id_info>
  <brief_title>An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165</brief_title>
  <acronym>Prism301</acronym>
  <official_title>A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety &amp; Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN 165 Self Administered by Adults With PKU Not Previously Treated With BMN 165</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioMarin Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BioMarin Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The BMN 165 clinical development program has been designed to demonstrate the safety and&#xD;
      efficacy of BMN 165 in reducing blood Phe concentrations in patients 18 to 70 years old with&#xD;
      hyperphenylalaninemia due to PKU. Study BMN 165-301 is a Phase 3, open-label, randomized&#xD;
      study designed to further characterize the safety of BMN 165 during two induction, titration,&#xD;
      and maintenance dose regimens in adults with PKU who have not had previous exposure to BMN&#xD;
      165 (naive). Subjects will be randomized (1:1) to titrate up to one of two dose regimens.&#xD;
      Other key features of this study are the dose regimens chosen for induction and titration;&#xD;
      the study duration; self administration of study drug; and the chosen tertiary objectives.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary and Secondary Outcomes:&#xD;
&#xD;
      The primary objective of the study is the following:&#xD;
&#xD;
        -  To characterize the safety and tolerability during induction, titration, and maintenance&#xD;
           dosing in BMN 165-naïve subjects who self administer BMN 165 at dose levels of 20 mg/day&#xD;
           and 40 mg/day&#xD;
&#xD;
      The secondary objective of the study is the following:&#xD;
&#xD;
        -  To evaluate blood Phe concentration during induction, titration, and maintenance dosing&#xD;
           in BMN 165-naïve subjects who self administer BMN 165 at dose levels of 20 mg/day and 40&#xD;
           mg/day&#xD;
&#xD;
      The tertiary objectives of the study are the following:&#xD;
&#xD;
        -  Percentage of daily recommended intake for age of natural protein intake&#xD;
&#xD;
        -  Dietary protein intake from medical food and intact food&#xD;
&#xD;
        -  The ADHD-RS score (-Investigator Rated; inattentive subscale score, total score, and&#xD;
           hyperactivity/impulsivity subscale score)&#xD;
&#xD;
        -  POMS scores (-Observer Rated and -Subject Rated)&#xD;
&#xD;
        -  Trough plasma concentrations of BMN 165&#xD;
&#xD;
      Primary Analysis:&#xD;
&#xD;
      All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). The&#xD;
      incidence of AEs will be summarized by system organ class, preferred term, relationship to&#xD;
      study drug, and severity for the subjects who are randomized to the 40 mg/day dose, the 20&#xD;
      mg/day dose, and overall. A by-subject listing will be provided for those subjects who&#xD;
      experience an SAE, including death, or experience an AE associated with early withdrawal from&#xD;
      the study or study drug. Hypersensitivity AEs and AEs that result in dosing interruption or&#xD;
      dose reduction are of interest, and the percentage of subjects who report these AEs will be&#xD;
      presented.&#xD;
&#xD;
      Clinical laboratory data will be summarized by the type of laboratory test for the subjects&#xD;
      who are randomized to the 40 mg/day dose, the 20 mg /day dose, and overall. Frequency and&#xD;
      percentage of subjects who experience abnormal (ie, outside of reference range) and/or&#xD;
      clinically significant abnormalities after study drug administration will be presented for&#xD;
      each clinical laboratory test. For each clinical laboratory test, descriptive statistics will&#xD;
      be provided for baseline and all subsequent post-baseline visits. Changes from baseline to&#xD;
      the post-baseline visits will also be provided. Descriptive statistics, including clinically&#xD;
      significant changes from baseline, of vital signs, physical examination results, ECG test&#xD;
      results, and immunogenicity test results will also be provided in a similar manner.&#xD;
      Additionally, antibodies and titers will be summarized at the scheduled time point.&#xD;
&#xD;
      Detailed statistical methods will be provided in the Statistical Analysis Plan (SAP).&#xD;
&#xD;
      Secondary Analysis:&#xD;
&#xD;
      The secondary efficacy endpoint is change from baseline to end of study in blood Phe&#xD;
      concentration.&#xD;
&#xD;
      Baseline is defined as the average of blood Phe concentrations collected prior to dosing at&#xD;
      the Screening Visit and on Day 1.&#xD;
&#xD;
      The primary analysis method for the secondary endpoint will use a repeated measures model,&#xD;
      with change from baseline Phe as the dependent variable and dose (40 mg/day or 20 mg/day),&#xD;
      study week, and baseline Phe as independent variables.&#xD;
&#xD;
      A responder analysis will be presented as a cumulative distribution function. The percentage&#xD;
      of subjects with blood Phe concentration below &quot;X&quot; umol/L at the end of the study will be&#xD;
      plotted and summarized for various &quot;X&quot; as a cumulative distribution function for each of the&#xD;
      2 doses and overall.&#xD;
&#xD;
      Detailed statistical methods will be provided in the SAP.&#xD;
&#xD;
      Tertiary Analyses:&#xD;
&#xD;
      The statistical analysis method for tertiary endpoints (protein intake; the ADHD-RS IV score)&#xD;
      will be descriptive. More details regarding the analysis methods for the tertiary endpoints&#xD;
      will be provided in the SAP.&#xD;
&#xD;
      Trough plasma concentrations of BMN 165 will be evaluated.&#xD;
&#xD;
      DMC The Data Monitoring Committee (DMC) will act in an advisory capacity to&#xD;
&#xD;
      BioMarin to monitor subject safety and the efficacy of BMN 165 in subjects who participate in&#xD;
      Study BMN 165-301 .The DMC responsibilities may include the following:&#xD;
&#xD;
        -  Review the study protocol, informed consent and assent documents, and plans for data&#xD;
           monitoring&#xD;
&#xD;
        -  Evaluate the progress of the trial; study data quality; timeliness; subject recruitment,&#xD;
           accrual and retention; subjects' risk versus benefit; and other factors that could&#xD;
           affect the study outcome&#xD;
&#xD;
        -  Consider relevant information that may have an effect on the safety of the participants&#xD;
           or the ethics of the study&#xD;
&#xD;
        -  Protect the safety of the study participants in accordance with the stopping rules as&#xD;
           defined in study protocol&#xD;
&#xD;
        -  Make recommendations to BioMarin concerning continuation or termination of the study or&#xD;
           other modifications of the study based on their observations&#xD;
&#xD;
        -  If appropriate, conduct interim analysis of safety and efficacy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">November 25, 2015</completion_date>
  <primary_completion_date type="Actual">November 25, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All subjects receive Study Drug. Subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day.Eligible subjects will be randomized 1:1 using an IWRS to titrate to one of two dose regimens:&#xD;
20 mg/day or 40 mg/day. The randomization will be stratified by blood Phe levels of 600 to 900 µmol/L and &gt;900 µmol/ using the last available blood Phe concentration prior to Day 1 of the study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Hypersensitivity Adverse Reaction</measure>
    <time_frame>baseline and 36 weeks</time_frame>
    <description>Hypersensitivity AEs will be identified in two ways:&#xD;
Broad Algorithmic anaphylactic reaction Standardized MedDRA Queries (SMQ)&#xD;
Modified Hypersensitivity SMQ to include above additional preferred terms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood Phenylalanine Concentration</measure>
    <time_frame>baseline and 36 weeks</time_frame>
    <description>Plasma phenylalanine (Phe) concentration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dietary Phenylalanine</measure>
    <time_frame>baseline and 36 weeks</time_frame>
    <description>All patients will complete a 3-day diet diary in order to assess dietary phenylalanine intake.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">261</enrollment>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>BMN 165, 20mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and &gt; 900 μmol/L).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMN 165, 40mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 mg/day or 40 mg/day. The randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600 to 900 μmol/L and &gt; 900 μmol/L).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMN 165</intervention_name>
    <description>After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the Induction Period, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until a minimum of approximately 26 weeks or a maximum of 36 weeks in the study.</description>
    <arm_group_label>BMN 165, 20mg/day</arm_group_label>
    <arm_group_label>BMN 165, 40mg/day</arm_group_label>
    <other_name>rAvPAL-PEG</other_name>
    <other_name>Pegvaliase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        Individuals eligible to participate in this study must meet all of the following criteria:&#xD;
&#xD;
          -  A current diagnosis of PKU with the following:&#xD;
&#xD;
               -  Current blood Phe concentration &gt;600 µmol/L at screening and&#xD;
&#xD;
               -  Average blood Phe concentration of &gt;600 µmol/L over the past 6 months (per&#xD;
                  available data)&#xD;
&#xD;
          -  Have no previous exposure to BMN 165&#xD;
&#xD;
          -  Are ≥18 and ≤70 years of age at the time of screening&#xD;
&#xD;
               -  Subjects who are &lt; 18 years of age but are already enrolled into the study may&#xD;
                  continue to participate&#xD;
&#xD;
          -  If taking Kuvan, have a treatment end date ≥14 days prior to Day 1 (ie, first dose of&#xD;
             BMN 165)&#xD;
&#xD;
          -  Are willing and able to provide written, signed informed consent after the nature of&#xD;
             the study has been explained and prior to any research-related procedures&#xD;
&#xD;
          -  Are willing and able to comply with all study procedures&#xD;
&#xD;
          -  Has identified a person who is ≥ 18 years of age who has the neurocognitive and&#xD;
             linguistic capacities to comprehend and complete the POMS-Observer-rated scale&#xD;
&#xD;
          -  Has identified a competent person or persons who are ≥ 18 years of age who can observe&#xD;
             the subject during study drug administration and for a minimum of 1 hour following&#xD;
             administration until dose titration has completed and if needed upon return to dosing&#xD;
             after an AE and per investigator determination.&#xD;
&#xD;
               -  A home healthcare nurse may perform the study drug observations.&#xD;
&#xD;
          -  For females of childbearing potential, must have a negative pregnancy test at&#xD;
             screening and be willing to have additional pregnancy tests during the study. (Females&#xD;
             are considered not of childbearing potential if they have been in menopause for at&#xD;
             least 2 years, have had a tubal ligation at least 1 year prior to screening, or have&#xD;
             had a total hysterectomy.)&#xD;
&#xD;
          -  If sexually active, must be willing to use 2 acceptable methods of contraception while&#xD;
             participating in the study and 4 weeks after the study.&#xD;
&#xD;
               -  Males post vasectomy 2 years with no known pregnancies for at least 2 years do&#xD;
                  not need to use any other forms of birth control during the study.&#xD;
&#xD;
               -  Females who have been in menopause for at least 2 years, have had a tubal&#xD;
                  ligation at least 1 year prior to screening, or have had a total hysterectomy do&#xD;
                  not need to use any other forms of contraception during the study.&#xD;
&#xD;
          -  Have received documented approval from a study dietician confirming that the subject&#xD;
             is capable of maintaining their diet in accordance with dietary information presented&#xD;
             in the protocol.&#xD;
&#xD;
          -  Have neurocognitive and linguistic capacities to comprehend and answer investigator's&#xD;
             prompts for the ADHD RS- Investigator rated instrument and to complete the&#xD;
             POMS-Subject rated scale.&#xD;
&#xD;
          -  If applicable, maintained stable dose of medication for attention deficit&#xD;
             hyperactivity disorder (ADHD), depression, anxiety, or other psychiatric disorder for&#xD;
             ≥8 weeks prior to enrollment and willing to maintain stable dose throughout study&#xD;
             unless a change is medically indicated.&#xD;
&#xD;
          -  Are in generally good health, as evidenced by physical examination, clinical&#xD;
             laboratory evaluations and ECG tests performed at screening&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        Individuals who meet any of the following exclusion criteria will not be eligible to&#xD;
        participate in the study:&#xD;
&#xD;
          -  Use of any investigational product or investigational medical device within 30 days&#xD;
             prior to screening or requirement for any investigational agent prior to completion of&#xD;
             all scheduled study assessments.&#xD;
&#xD;
          -  Use of any medication that is intended to treat PKU (except Kuvan), including the use&#xD;
             of large neutral amino acids, within 2 days prior to administration of study drug Day&#xD;
             1 (first dose of BMN 165). Note: Kuvan treatment must be stopped ≥14 days before Day 1&#xD;
&#xD;
          -  Use or planned use of any injectable drugs containing PEG (other than BMN 165),&#xD;
             including medroxyprogesterone injection, within 3 months prior to screening and during&#xD;
             study participation&#xD;
&#xD;
          -  Known hypersensitivity to any components of BMN 165&#xD;
&#xD;
          -  Current use of levodopa&#xD;
&#xD;
          -  A positive test for HIV antibody, hepatitis B surface antigen, or hepatitis C antibody&#xD;
&#xD;
          -  A history of organ transplantation or on chronic immunosuppressive therapy&#xD;
&#xD;
          -  A history of substance abuse (as defined by the Diagnostic and Statistical Manual of&#xD;
             Mental Disorders [DSM IV]) in the past 12 months or current alcohol or drug abuse&#xD;
&#xD;
          -  Current participation in the Kuvan registry study (PKU Demographics, Outcomes and&#xD;
             Safety [PKUDOS]). Patients may discontinue the PKUDOS registry trial to allow&#xD;
             enrollment in this study&#xD;
&#xD;
          -  Pregnant or breastfeeding at screening or planning to become pregnant (self or&#xD;
             partner) or breastfeed at any time during the study&#xD;
&#xD;
          -  Concurrent disease or condition that would interfere with study participation or&#xD;
             safety (eg, history or presence of clinically significant cardiovascular, pulmonary,&#xD;
             hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,&#xD;
             neurological, oncologic, or psychiatric disease)&#xD;
&#xD;
          -  Major surgery planned during the study period&#xD;
&#xD;
          -  Any condition that, in the view of the investigator, places the subject at high risk&#xD;
             of poor treatment compliance or terminating early from the study&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) concentration ≥2 times the upper limit of normal&#xD;
&#xD;
          -  Creatinine &gt;1.5 times the upper limit of normal.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Merilainen, MD</last_name>
    <role>Study Director</role>
    <affiliation>BioMarin Pharmaceutical</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Altman Clinical and Translational Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Clinical Research Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Health System</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Universty</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann and Robert H Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Children's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weisskopf Child Evaluation Center / University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Center for Applied Research Sciences</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper Health Systems</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System - Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Cleveland, Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Christopher's Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmrn.com</url>
    <description>Biomarin Pharmaceutical website</description>
  </link>
  <link>
    <url>http://www.pku.com/</url>
    <description>BioMarin sponsored PKU educational/community website</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 18, 2013</study_first_submitted>
  <study_first_submitted_qc>March 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2013</study_first_posted>
  <results_first_submitted>June 22, 2018</results_first_submitted>
  <results_first_submitted_qc>August 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2018</results_first_posted>
  <disposition_first_submitted>August 17, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>August 17, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 21, 2017</disposition_first_posted>
  <last_update_submitted>February 6, 2019</last_update_submitted>
  <last_update_submitted_qc>February 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PKU</keyword>
  <keyword>PEG-PAL</keyword>
  <keyword>BioMarin</keyword>
  <keyword>rAv-PAL PEG</keyword>
  <keyword>BMN 165</keyword>
  <keyword>open label</keyword>
  <keyword>Prism301</keyword>
  <keyword>Pegvaliase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BMN 165, 20mg/Day</title>
          <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
        </group>
        <group group_id="P2">
          <title>BMN 165, 40mg/Day</title>
          <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to demostrate ability self-inject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Quit due to lack of health benifits</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BMN 165, 20mg/Day</title>
          <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
        </group>
        <group group_id="B2">
          <title>BMN 165, 40mg/Day</title>
          <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
            <count group_id="B2" value="130"/>
            <count group_id="B3" value="261"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.2" spread="8.63"/>
                    <measurement group_id="B2" value="28.1" spread="8.77"/>
                    <measurement group_id="B3" value="29.2" spread="8.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>16 - &lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>18 - &lt;66 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="253"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="131"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hypersensitivity Adverse Reaction</title>
        <description>Hypersensitivity AEs will be identified in two ways:&#xD;
Broad Algorithmic anaphylactic reaction Standardized MedDRA Queries (SMQ)&#xD;
Modified Hypersensitivity SMQ to include above additional preferred terms</description>
        <time_frame>baseline and 36 weeks</time_frame>
        <population>The safety population will consist of all subjects who receive any pegvaliase throughout the study duration. The safety population will be analyzed according to the treatment assignment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>BMN 165, 20mg/Day</title>
            <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
          </group>
          <group group_id="O2">
            <title>BMN 165, 40mg/Day</title>
            <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypersensitivity Adverse Reaction</title>
          <description>Hypersensitivity AEs will be identified in two ways:&#xD;
Broad Algorithmic anaphylactic reaction Standardized MedDRA Queries (SMQ)&#xD;
Modified Hypersensitivity SMQ to include above additional preferred terms</description>
          <population>The safety population will consist of all subjects who receive any pegvaliase throughout the study duration. The safety population will be analyzed according to the treatment assignment actually received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Phenylalanine Concentration</title>
        <description>Plasma phenylalanine (Phe) concentration</description>
        <time_frame>baseline and 36 weeks</time_frame>
        <population>The intent-to-treat (ITT) population will consist of all subjects who are randomized to study treatment whether or not treatment was received.</population>
        <group_list>
          <group group_id="O1">
            <title>BMN 165, 20mg/Day</title>
            <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
          </group>
          <group group_id="O2">
            <title>BMN 165, 40mg/Day</title>
            <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Phenylalanine Concentration</title>
          <description>Plasma phenylalanine (Phe) concentration</description>
          <population>The intent-to-treat (ITT) population will consist of all subjects who are randomized to study treatment whether or not treatment was received.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1241.0" spread="389.70"/>
                    <measurement group_id="O2" value="1224.4" spread="384.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="868.4" spread="501.78"/>
                    <measurement group_id="O2" value="624.4" spread="530.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Dietary Phenylalanine</title>
        <description>All patients will complete a 3-day diet diary in order to assess dietary phenylalanine intake.</description>
        <time_frame>baseline and 36 weeks</time_frame>
        <population>The intent-to-treat (ITT) population will consist of all subjects who are randomized to study treatment whether or not treatment was received.</population>
        <group_list>
          <group group_id="O1">
            <title>BMN 165, 20mg/Day</title>
            <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
          </group>
          <group group_id="O2">
            <title>BMN 165, 40mg/Day</title>
            <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Dietary Phenylalanine</title>
          <description>All patients will complete a 3-day diet diary in order to assess dietary phenylalanine intake.</description>
          <population>The intent-to-treat (ITT) population will consist of all subjects who are randomized to study treatment whether or not treatment was received.</population>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1750.8" spread="1168.91"/>
                    <measurement group_id="O2" value="1647.9" spread="1222.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1851.8" spread="1145.06"/>
                    <measurement group_id="O2" value="2057.9" spread="1448.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 0- Week 36</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BMN 165, 20mg/Day</title>
          <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
        </group>
        <group group_id="E2">
          <title>BMN 165, 40mg/Day</title>
          <description>Subjects who meet the eligibility criteria will be randomized 1:1 to titrate to one of two dose regimens: 20 or 40 mg/day. Randomization will be stratified by the last available blood Phe concentration prior to Day 1 (600-900 μmol/L and &gt; 900 μmol/L). All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction). After the IP, subjects will enter the Titration Period (Weeks 5 up to 34) where they will increase their weekly dose to a daily dose regimen of 20 or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the amount of time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 30 weeks (accounts for dose reduction or interruption due to AEs). Subjects will stop titration once they have achieved either the 20 or 40 mg/day dose regimen. The majority of subjects will maintain the 20 or 40 mg/day dose regimen for at least an additional 2 weeks until 26 weeks-36 weeks in the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Electrocution</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Puncture site haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="21" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E2" events="18" subjects_affected="10" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="131"/>
                <counts group_id="E2" events="28" subjects_affected="22" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="33" subjects_affected="21" subjects_at_risk="131"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="131"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="58" subjects_affected="21" subjects_at_risk="131"/>
                <counts group_id="E2" events="27" subjects_affected="13" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="65" subjects_affected="24" subjects_at_risk="131"/>
                <counts group_id="E2" events="44" subjects_affected="26" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="323" subjects_affected="57" subjects_at_risk="131"/>
                <counts group_id="E2" events="210" subjects_affected="61" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" events="112" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="63" subjects_affected="27" subjects_at_risk="131"/>
                <counts group_id="E2" events="55" subjects_affected="29" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="87" subjects_affected="29" subjects_at_risk="131"/>
                <counts group_id="E2" events="119" subjects_affected="36" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="96" subjects_affected="22" subjects_at_risk="131"/>
                <counts group_id="E2" events="66" subjects_affected="28" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="700" subjects_affected="80" subjects_at_risk="131"/>
                <counts group_id="E2" events="495" subjects_affected="68" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="70" subjects_affected="23" subjects_at_risk="131"/>
                <counts group_id="E2" events="45" subjects_affected="20" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" events="27" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" events="25" subjects_affected="14" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" events="22" subjects_affected="9" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="22" subjects_at_risk="131"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="43" subjects_affected="26" subjects_at_risk="131"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="131"/>
                <counts group_id="E2" events="29" subjects_affected="25" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="22" subjects_at_risk="131"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="26" subjects_affected="17" subjects_at_risk="131"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cortisol decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Complement factor C3 decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Complement factor C4 decreased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="376" subjects_affected="78" subjects_at_risk="131"/>
                <counts group_id="E2" events="350" subjects_affected="92" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="21" subjects_at_risk="131"/>
                <counts group_id="E2" events="26" subjects_affected="20" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E2" events="24" subjects_affected="19" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="42" subjects_affected="20" subjects_at_risk="131"/>
                <counts group_id="E2" events="52" subjects_affected="26" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="131"/>
                <counts group_id="E2" events="32" subjects_affected="21" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="112" subjects_affected="46" subjects_at_risk="131"/>
                <counts group_id="E2" events="98" subjects_affected="36" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="131"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E2" events="28" subjects_affected="12" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="39" subjects_affected="22" subjects_at_risk="131"/>
                <counts group_id="E2" events="65" subjects_affected="25" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="68" subjects_affected="27" subjects_at_risk="131"/>
                <counts group_id="E2" events="83" subjects_affected="40" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" events="17" subjects_affected="8" subjects_at_risk="130"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="71" subjects_affected="18" subjects_at_risk="131"/>
                <counts group_id="E2" events="101" subjects_affected="30" subjects_at_risk="130"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Scientist I, Clinical Sciences</name_or_title>
      <organization>BioMarin Pharmaceutical Inc.</organization>
      <phone>415-506-6348</phone>
      <email>dlounsbury@bmrn.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

